<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675622</url>
  </required_header>
  <id_info>
    <org_study_id>OXYC10-CN-303</org_study_id>
    <nct_id>NCT01675622</nct_id>
  </id_info>
  <brief_title>Immediate-Release Oxycodone Capsules Study in Cancer Pain</brief_title>
  <official_title>A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Pte Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of dose titration of OxyNorm™ immediate-release capsules versus morphine
      immediate-release tablets in the treatment of cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of dose titration of OxyNorm™ immediate-release capsules versus
      morphine immediate-release tablets in the treatment of cancer pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1. NRS (Numerical Rating Scale) score</measure>
    <time_frame>5-8 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the average for decrease of NRS score after double blind treatment between the two treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The average dose of study medicine used during double blind treatment period</measure>
    <time_frame>5-8 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the average dose of study medicine used during double blind treatment period between the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. BPI (Brief pain inventory)</measure>
    <time_frame>19-22 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare BPI score at baseline, after completion of double blind treatment and open label treatment to baseline between the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Times / frequency of breakthrough pain and the total dose of rescue medicine for breakthrough pain.</measure>
    <time_frame>19-22 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the times/frequency of breakthrough pain and the total dose of rescue medicine for breakthrough pain during double blind phase between the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessments of satisfaction for pain management</measure>
    <time_frame>19-22 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare patient assessments of satisfaction for pain management between the two treatment groups at the end of double blind treatment and the open label treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time for titration</measure>
    <time_frame>1-3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the average time for titration between the two treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Oxycodone Capsule for cancer pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine tablets for cancer pain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:5-8 days</description>
    <arm_group_label>Oxycodone Capsule for cancer pain</arm_group_label>
    <other_name>No other name in this study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine tablets 10mg and 20mg, Oral by 4-6 hours</description>
    <arm_group_label>Morphine tablets for cancer pain</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of either sex aged 18 to 80 years inclusive, who with cancers of all type.

          2. Patients with moderate to severe cancer pain, whose pain intensity NRS ≥4.

          3. Patients who can understand and are able to complete NRS and BPI assessment.

          4. Patients who have given written informed consent to participate in the study.

        Exclusion Criteria:

          1. Patients who are pregnant, or lactating.

          2. Patients who are unable to manage their pain effectively with opioids.

          3. Patient who need ≥120mg morphine or equivalent for treatment of pain at time of study
             entry;

          4. Patients who are receiving chemotherapy, or still under the responsive period of
             chemotherapy (patients who are at the interval period of chemotherapy can be enrolled
             into study. That is to say, patients who completed chemotherapy for more than 2 weeks
             can enrolled, or patients has completed chemotherapy for at least one week could be
             enrolled at the discretion of the investigator).

          5. Patients who have received radio-therapy for bony metastasis, patients receiving
             radiotherapy within the 4 week period before study entry (patient receiving
             radiotherapy for area other than pain area can be enrolled) , or patients who were
             scheduled to receive radiotherapy for pain area during study period.

          6. Patients are receiving or should receive anti-convulsion drugs/anti- depression drugs
             considered by investigator for the treatment of neuropathy pain. Patients are
             receiving or should receive any analgesic other than study medicine, which including
             NSAIDs.

          7. Patients with other unstable disease, or with dysfunction of important organ.

          8. Patients with an ongoing infection, abscess or fever.

          9. Patient with serious abnormal liver/ renal function (ALT/AST/creatinine/urea
             nitrogen) which is higher than 3 times of upper limit;

         10. Paralytic or mechanical ileus;

         11. Persistent asthma, chronic obstructive diseases, and cor pulmonary;

         12. Intracranial neoplasms, and intracranial hypertension with central respiratory
             depression risk.

         13. Monoamine oxidase inhibitors (MAOIs) or same type drugs have been administered in
             last 2 weeks;

         14. Patients who are currently taking active treatment for epilepsy or arrhythmias.

         15. Patients with known sensitivity or record of specific or allergic reaction to
             oxycodone or morphine.

         16. Patients excluded by the contra-indications, adverse drug reaction (ADRs) and drug
             interactions of oxycodone or morphine as detailed in the data sheet, summary of
             product characteristics or investigator's brochure.

         17. Patients with a history of drug or alcohol abuse.

         18. Patients who participated in another clinical research study involving a new chemical
             entity within one month prior to study entry.

         19. Patients whose concomitant medication is likely to be changed within the study
             period, with the exception of treatment for opioid side effects.

         20. Patients who, in the opinion of the investigator, are unsuitable to participate in
             the study for any other reason not mentioned in the inclusion and exclusion criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiying Yu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan TongJi Hospital</affiliation>
  </overall_official>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>October 8, 2012</lastchanged_date>
  <firstreceived_date>April 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
